A large Intermountain Health randomized trial published in JAMA found that starting vasopressin early in septic shock patients did not improve survival or recovery compared with waiting until the condition worsened. The negative outcome is a direct challenge to early-initiation protocols and will affect bedside decision-making around vasopressor selection and timing. It also narrows the evidence base for whether vasopressin timing changes trajectories in a disease state defined by rapid physiologic deterioration. For critical care teams, the study reinforces that escalation strategies need outcome-validated timing rather than physiology-based assumptions.